<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00391157</url>
  </required_header>
  <id_info>
    <org_study_id>2005-000186-19</org_study_id>
    <secondary_id>VELCADEXA</secondary_id>
    <nct_id>NCT00391157</nct_id>
  </id_info>
  <brief_title>VELCADEXA: Velcade and Dexamethasone in Multiple Myeloma</brief_title>
  <official_title>VELCADEXA: A National, Multi-Center, Open-Label Study of Pretransplant Induction With Alternating VELCADE and Dexamethasone (VEL/Dex) in Younger (&lt; 65 Yrs) Untreated Multiple Myeloma Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PETHEMA Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PETHEMA Foundation</source>
  <brief_summary>
    <textblock>
      The primary efficacy objective of this study is to study the efficacy in terms of response
      rate to alternating bortezomib/dexamethasone regimen
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple Myeloma is a plasma cell disorder characterized by an uncontrolled proliferation of
      bone marrow plasma cells leading to skeletal destruction with bone pain, anemia, renal
      failure, hypercalcemia, recurrent bacterial infections and extramedullary plasmacytomas. It
      accounts for 1% of all malignancies and slightly more than 10% of hematologic malignancies,
      with an annual incidence of about four per 100.000. Although this disease is incurable with a
      median survival of about 3 years, remarkable treatment advances have been recently made,
      including high-dose therapy followed by stem cell rescue and, particularly, the introduction
      of novel promising agents with new mechanisms of action.

      Data from pre-clinical and clinical studies conducted to date support the continued
      development of VELCADE for the treatment of Multiple Myeloma. Standard chemotherapy remains
      as the gold standard for induction before HDT/SCT treatment in younger multiple myeloma
      patients (&lt;65 years). Since VELCADE has a mechanism of action different from chemotherapy and
      dexamethasone and is considered to be efficacious in Multiple Myeloma, its introduction in
      induction regimens may contribute to increase the response rate and eventually survival of
      these patients that represent half of myeloma population.

      Since VBMCP/VBAD is considered to be the gold standard for Multiple Myeloma patients &lt;65
      years as induction regimen prior HDT/SCT, the results of VEL/DEX will be compared with those
      obtained in 100 patients treated with VBMCP/VBAD chemotherapy in our last GEM protocol
      (Spanish Myeloma Group) for patients &lt;65 years (closed in Dec 2004
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the efficacy of velcade and dexamethasone with chemotherapy combination VBMCP/VBAD</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the quality of progenitors cells after treatment with Velcade and dexamethasone</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the complete response rate after high dose therapy in patients treated with velcade and dexamethasone or VBMCP/VBAD</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">40</enrollment>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Velcade/Dexamethasone</intervention_name>
    <description>Velcade 1,3 mg/m2 on days 1, 4, 8 and 11</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is, in the investigator's opinion, willing and able to comply with the
             protocol requirements.

          -  Patient has given voluntary written informed consent before performance of any
             study-related procedure not part of normal medical care, with the understanding that
             consent may be withdrawn by the patient at any time without prejudice to their future
             medical care.

          -  Age over 18 and under 65 years old.

          -  Patient recently diagnosed with symptomatic Multiple Myeloma based on standard
             criteria and that has not received any previous chemotherapy treatment for Multiple
             Myeloma.

          -  Patient has measurable disease, defined as follows:

        For secretory multiple myeloma, measurable disease is defined as any quantifiable serum
        monoclonal protein value and, where applicable, urine light-chain excretion of ≥ 200 mg/24
        hours.

        For poor or non-secretory multiple myeloma, measurable disease is defined by the presence
        of soft tissue (not bone) plasmacytomas as determined by clinical examination or applicable
        radiographs (i.e. MRI, CT-Scan). In patients with oligosecretory multiple myeloma, the
        serum and/or urine M-protein measurements are very low and difficult to follow for response
        assessment. In patients with non-secretory multiple myeloma, there is no M-protein in serum
        or urine by immunofixation.

          -  Patient has a ECOG performance status &lt; 2.

          -  Patient has a life-expectancy &gt;3 months.

          -  Patient has the following laboratory values within 14 days before Baseline visit (Day
             1 of Cycle 1, before study drug administration):

        Platelet count ≥ 50x109/L, hemoglobin ≥ 8 g/dl and absolute neutrophil count (ANC) ≥
        1.0x109/L; Corrected serum calcium &lt;14mg/dl. Aspartate transaminase (AST): ≤ 2.5 x the
        upper limit of normal. Alanine transaminase (ALT): ): ≤ 2.5 x the upper limit of normal.
        Total bilirubin: ≤1.5 x the upper limit of normal. Serum creatinine value ≤ 2mg/dl

        Exclusion Criteria:

          -  Patient previously received treatment with VELCADE.

          -  Patient previously received treatment for Multiple Myeloma

          -  Patient had major surgery within 4 weeks before enrollment.

          -  Patient has a platelet count &lt; 50x 109/L within 14 days before enrollment.

          -  Patient has an absolute neutrophil count &lt; 1.0 x 109/L within 14 days before
             enrollment.

          -  Patient has &lt; Grade 2 peripheral neuropathy within 14 days before enrollment.

          -  Patient has hypersensitivity to bortezomib, boron or mannitol.

          -  Patient has received other investigational drugs within 14 days before enrollment.

          -  Patient is known to be seropositive for the human immunodeficiency virus (HIV),
             Hepatitis B surface antigen-positive or active hepatitis C infection.

          -  Patient had a myocardial infarction within 6 months of enrollment or has New York
             Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe
             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
             ischemia or active conduction system abnormalities.

          -  Patient is enrolled in another clinical research study and/or is receiving an
             investigational agent for any reason.

          -  Pregnancy, breast-feeding or fertile women who are not going to use a medical
             effective contraceptive method during the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bladé Joan, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clínica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos de Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Doce de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Segovia</name>
      <address>
        <city>Segovia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.aehh.org</url>
    <description>Spanish association of Haematology</description>
  </link>
  <reference>
    <citation>Longo D. Plasma cell disorders. In: Fauce A, et al. Ed. Harrison's Principles of Internal Medicine. 14th Ed. New York, New York: Mc Graw-Hill; 1998: 712-718.</citation>
  </reference>
  <reference>
    <citation>Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33.</citation>
    <PMID>10735013</PMID>
  </reference>
  <reference>
    <citation>Raje N, Anderson K. Thalidomide--a revival story. N Engl J Med. 1999 Nov 18;341(21):1606-9.</citation>
    <PMID>10564693</PMID>
  </reference>
  <reference>
    <citation>Oken MM. Management of Myeloma: Current and Future Approaches. Cancer Control. 1998 May;5(3):218-225.</citation>
    <PMID>10761055</PMID>
  </reference>
  <reference>
    <citation>Westin J. Conventional chemotherapy in multiple myeloma. Pathol Biol (Paris). 1999 Feb;47(2):169-71.</citation>
    <PMID>10192883</PMID>
  </reference>
  <reference>
    <citation>Huang YW, Hamilton A, Arnuk OJ, Chaftari P, Chemaly R. Current drug therapy for multiple myeloma. Drugs. 1999 Apr;57(4):485-506. Review.</citation>
    <PMID>10235689</PMID>
  </reference>
  <reference>
    <citation>Smith ML, Newland AC. Treatment of myeloma. QJM. 1999 Jan;92(1):11-4. Review.</citation>
    <PMID>10209667</PMID>
  </reference>
  <reference>
    <citation>Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med. 1997 Jun 5;336(23):1657-64. Review.</citation>
    <PMID>9171069</PMID>
  </reference>
  <reference>
    <citation>Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med. 1994 Feb 17;330(7):484-9. Review.</citation>
    <PMID>8289856</PMID>
  </reference>
  <reference>
    <citation>Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol. 1992 Feb;10(2):334-42.</citation>
    <PMID>1531068</PMID>
  </reference>
  <reference>
    <citation>Case DC Jr, Lee DJ 3rd, Clarkson BD. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol. Am J Med. 1977 Dec;63(6):897-903.</citation>
    <PMID>605911</PMID>
  </reference>
  <reference>
    <citation>Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol. 1990 Feb;33(2):86-9.</citation>
    <PMID>2301376</PMID>
  </reference>
  <reference>
    <citation>Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood. 1992 Aug 15;80(4):887-90.</citation>
    <PMID>1498331</PMID>
  </reference>
  <reference>
    <citation>Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med. 1996 Jul 11;335(2):91-7.</citation>
    <PMID>8649495</PMID>
  </reference>
  <reference>
    <citation>Alexanian R, Weber D, Giralt S, Dimopoulos M, Delasalle K, Smith T, Champlin R. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant. 2001 May;27(10):1037-43.</citation>
    <PMID>11438818</PMID>
  </reference>
  <reference>
    <citation>Nadal E, Giné E, Bladé J, Esteve J, Rosiñol L, Fernández-Avilés F, Marin P, Martinez C, Rovira M, Urbano-Ispizua A, Carreras E, Montserrat E. High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission. Bone Marrow Transplant. 2004 Jan;33(1):61-4.</citation>
    <PMID>14704657</PMID>
  </reference>
  <reference>
    <citation>Driscoll J. The role of the proteasome in cellular protein degradation. Histol Histopathol. 1994 Jan;9(1):197-202. Review.</citation>
    <PMID>8003815</PMID>
  </reference>
  <reference>
    <citation>Richter-Ruoff B, Wolf DH. Proteasome and cell cycle. Evidence for a regulatory role of the protease on mitotic cyclins in yeast. FEBS Lett. 1993 Dec 20;336(1):34-6.</citation>
    <PMID>8262212</PMID>
  </reference>
  <reference>
    <citation>Goldberg AL, Stein R, Adams J. New insights into proteasome function: from archaebacteria to drug development. Chem Biol. 1995 Aug;2(8):503-8. Review.</citation>
    <PMID>9383453</PMID>
  </reference>
  <reference>
    <citation>Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001 Apr 1;61(7):3071-6.</citation>
    <PMID>11306489</PMID>
  </reference>
  <reference>
    <citation>Sherr CJ. Cancer cell cycles. Science. 1996 Dec 6;274(5293):1672-7. Review.</citation>
    <PMID>8939849</PMID>
  </reference>
  <reference>
    <citation>Koepp DM, Harper JW, Elledge SJ. How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell. 1999 May 14;97(4):431-4. Review.</citation>
    <PMID>10338207</PMID>
  </reference>
  <reference>
    <citation>Read MA, Neish AS, Luscinskas FW, Palombella VJ, Maniatis T, Collins T. The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity. 1995 May;2(5):493-506.</citation>
    <PMID>7538441</PMID>
  </reference>
  <reference>
    <citation>Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell. 1994 Sep 9;78(5):773-85.</citation>
    <PMID>8087845</PMID>
  </reference>
  <reference>
    <citation>Zetter BR. Adhesion molecules in tumor metastasis. Semin Cancer Biol. 1993 Aug;4(4):219-29. Review.</citation>
    <PMID>8400144</PMID>
  </reference>
  <reference>
    <citation>Beg AA, Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science. 1996 Nov 1;274(5288):782-4.</citation>
    <PMID>8864118</PMID>
  </reference>
  <reference>
    <citation>Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest. 2001 Feb;107(3):241-6. Review.</citation>
    <PMID>11160144</PMID>
  </reference>
  <reference>
    <citation>McConkey DJ, Pettaway C, Elliott P, et al. The proteasome as a new drug target in metastatic prostate cancer. ATMDACC 7th Annual Genitourinary Oncology Conference, 1998.</citation>
  </reference>
  <reference>
    <citation>Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999 Jun 1;59(11):2615-22.</citation>
    <PMID>10363983</PMID>
  </reference>
  <reference>
    <citation>Millenium Pharmaceuticals, Inc. (PS-341) Investigator's Brochure, Version 5.0, 2001</citation>
  </reference>
  <reference>
    <citation>Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003 Jun 26;348(26):2609-17.</citation>
    <PMID>12826635</PMID>
  </reference>
  <reference>
    <citation>Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998 Sep;102(5):1115-23.</citation>
    <PMID>9753033</PMID>
  </reference>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2006</study_first_submitted>
  <study_first_submitted_qc>October 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2006</study_first_posted>
  <last_update_submitted>September 17, 2009</last_update_submitted>
  <last_update_submitted_qc>September 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>pethema</name_title>
    <organization>pethema</organization>
  </responsible_party>
  <keyword>Múltiple Myeloma</keyword>
  <keyword>Transplant</keyword>
  <keyword>Patients &lt;65 years.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

